Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia
作者:Samar J. Almehmadi、Amani M.R. Alsaedi、Marwa F. Harras、Thoraya A. Farghaly
DOI:10.1016/j.bioorg.2021.105431
日期:2021.12
Based on the structural study of previously known CDK2 inhibitors, a new series of pyrazolo[1,5-a]pyrimidine derivatives was designed and synthesized. The target compounds were biologically assessed as potent CDK2 inhibitors and promising anti-leukemia hits. The 7-(4-Bromo-phenyl)-3-(3-chloro/2-chloro-phenylazo)-pyrazolo[1,5-a]pyrimidin-2-ylamines 5 h and 5i revealed the best CDK2 inhibitory activity
基于先前已知的CDK2抑制剂的结构研究,设计并合成了一系列新的吡唑并[1,5- a ]嘧啶衍生物。目标化合物在生物学上被评估为有效的 CDK2 抑制剂和有希望的抗白血病命中。7-(4-溴-苯基)-3-(3-氯/2-氯-苯偶氮)-吡唑并[1,5 - a ]嘧啶-2-基胺5 h和5i显示出最好的CDK2抑制活性,具有可比性药效( IC 50 = 22 和 24 nM,分别)与 dinaciclib(IC 50 = 18 nM)相比。此外,两种类似物在纳摩尔浓度(IC 50 = 28–80 nM)。目标化合物的抗白血病筛选显示对使用的白血病细胞系(MOLT-4 和 HL-60)具有强至中度的细胞毒性。与 dinaciclib (IC 50 = 1.30 和 1.84 µM) 相比,化合物5 h分别抑制 MOLT-4 和 HL-60 1.4 和 2.3 倍 (IC 50 = 0.93 和 0